Stay Updated

Sign up to our newsletter to get the latest updates

Meet our new Scientific Advisory Board!

Renowned experts bring decades of experience to Beckley Psytech

Our Scientific Advisory Board comprises some of the world’s most respected figures from across the fields of psychiatric and psychedelic research. The Board advises on our development of a pipeline of psychedelic drugs into licensed pharmaceutical medicines for treating debilitating psychiatric and neurological diseases.

It is chaired by Beckley Psytech cofounder Amanda Feilding, who founded the Beckley Foundation in 1998 as a non-profit NGO focused on scientific research into psychedelic medicines.

Through the Foundation, Amanda has collaborated with many of the Scientific Advisory Board’s members on some of the most groundbreaking studies in psychedelic science to date. She is delighted to join forces with the experts once again, this time with the specific aim of working towards treatments that can, one day, be integrated into mainstream medical practice.

You can find out more about the Board and its members, including their work with the Beckley Foundation and contributions to the fields of psychedelic and psychiatric science, below:

Dr Robin L Carhart-Harris PhD, Director of the Centre for Psychedelic Research at Imperial College London

Dr Robin L. Carhart-Harris PhD founded the Psychedelic Research Group at Imperial College London in 2015 and has worked closely with Beckley Psytech’s strategic partner the Beckley Foundation on a series of ground-breaking brain imaging studies into the effects of psilocybin, MDMA, LSD and DMT, as well as clinical trials of psilocybin for treatment-resistant depression. He holds a PhD in Psychopharmacology from the University of Bristol and an honorary position at the University of Oxford. 

Professor Matthew W. Johnson PhD, Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine

Professor Matthew Johnson is one of the world’s most published scientists on the human effects of psychedelics. Working with psychedelics since 2004, he published psychedelic safety guidelines in 2008 which helped resurrect psychedelic research, before publishing the largest ever study of psilocybin in treating cancer distress in 2016. In a 2014 study sponsored by the Beckley Foundation, he researched the effects of psilocybin on breaking tobacco addiction and was immensely successful, with 80% of patients smoke free. Matthew is President of the International Society for Research on Psychedelics.

Frederick Reinholdt MA, Senior Therapist in Psychedelics at The Institute of Psychiatry, Psychology and Neuroscience, King’s College London

Before moving into research, Frederick Reinholdt MA maintained a 30-year clinical career as a psychotherapist in a community setting. After 15 years with the Johns Hopkins Community Psychiatry Program, he transitioned to the Johns Hopkins School of Medicine, where he served as a lead therapist in multiple research studies on the efficacy of psilocybin-assisted therapies. He is Senior Therapist in Psychedelics at The Institute of Psychiatry, Psychology & Neuroscience, King’s College London.

Professor Guy Goodwin FMedSci, Senior Research Fellow, Department of Psychiatry; Emeritus Fellow, Merton College

Professor Guy Goodwin is Senior Research Fellow at the University of Oxford. From 1996 to 2014, he was WA Handley Professor of Psychiatry and headed the Department of Psychiatry until 2011, with research interests in the treatment of bipolar disorder and the application of neuroscience in understanding the neurobiology and treatment of mood disorders. He has also held the coveted positions of President of the British Association for Psychopharmacology, President of the European College of Neuropsychopharmacology, and Senior Investigator on the faculty of UK National Institute for Health Research.

More Like This

Company Announcements

Beckley Psytech bolsters pipeline of next-generation psychedelic medicines with research collaborati...

Beckley Psytech to collaborate with Lophora on researching New Clinical Entities (NCE’s) Broad collaboration with Lophora will further strengthen Beckley Psytech’s world class management and R&D team

Company Announcements

Beckley Psytech announces partnership with Empatica in latest step of digital strategy, designed to ...

Partnership will capture behavioural and physiological signals and predictive biomarkers in Beckley Psytech’s upcoming Phase 2 clinical trials. New digital strategy aims to improve patient outcomes and safety by integrating advanced digital tools i... Read More

Company Announcements

Beckley Psytech announces dosing of first healthy volunteers in Phase 1 clinical trial assessing saf...

Study represents continued efforts to further understand the clinical and pharmacological potential of 5-MeO-DMT. BPL-003 is Beckley Psytech’s innovative dry powder intranasal formulation of 5-MeO-DMT using FDA approved intranasal delivery devices.... Read More